Selected research
Market Structure
Global Neurodegenerative Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Neurodegenerative Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Neurodegenerative Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Neurodegenerative Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Neurodegenerative Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Neurodegenerative Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Neurodegenerative Disease include Biogen Idec, Boehringer Ingelheim, Merck Serono, UCB, BORA PHARMACEUTICALS, Dongcheng Biochemicals, Ark Pharmaceutical, GlaxoSmithKline and Haisco Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Neurodegenerative Disease market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Neurodegenerative Disease and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Neurodegenerative Disease revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Neurodegenerative Disease market size, projected growth trends, production technologies, key applications, and end-use industries.
Neurodegenerative Disease Segment by Company
Biogen Idec
Boehringer Ingelheim
Merck Serono
UCB
BORA PHARMACEUTICALS
Dongcheng Biochemicals
Ark Pharmaceutical
GlaxoSmithKline
Haisco Pharmaceutical
Hisun Pharmaceutical
Huahai Pharmaceutical
Pfizer
Jingxin Pharmaceutical
Kanghong Pharmaceutical
Livzon Pharmaceutical
Luye Pharma
Novartis
Sanofi
TEVA
Neurodegenerative Disease Segment by Type
NMDA
SSRIs
Dopamine Inhibitors
Neurodegenerative Disease Segment by Application
Alzheimer’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Parkinson’s Disease
Neurodegenerative Disease Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Neurodegenerative Disease in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurodegenerative Disease industry.
Chapter 3: Detailed analysis of Neurodegenerative Disease companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurodegenerative Diseaserevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- NMDA
- SSRIs
- Dopamine Inhibitors
Applications
- Alzheimer’s Disease
- Huntington Disease
- Amyotrophic Lateral Sclerosis
- Parkinson’s Disease
Companies covered
- Biogen Idec
- Boehringer Ingelheim
- Merck Serono
- UCB
- BORA PHARMACEUTICALS
- Dongcheng Biochemicals
- Ark Pharmaceutical
- GlaxoSmithKline
- Haisco Pharmaceutical
- Hisun Pharmaceutical
- Huahai Pharmaceutical
- Pfizer
- Jingxin Pharmaceutical
- Kanghong Pharmaceutical
- Livzon Pharmaceutical
- Luye Pharma
- Novartis
- Sanofi
- TEVA
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Neurodegenerative Disease Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 NMDA
- 1.2.3 SSRIs
- 1.2.4 Dopamine Inhibitors
- 1.3 Market Analysis by Application
- 1.3.1 Global Neurodegenerative Disease Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Alzheimer’s Disease
- 1.3.3 Huntington Disease
- 1.3.4 Amyotrophic Lateral Sclerosis
- 1.3.5 Parkinson’s Disease
- 1.4 Global Market Growth Prospects
- 1.5 Global Neurodegenerative Disease Growth Trends by Region
- 1.5.1 Global Neurodegenerative Disease Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Neurodegenerative Disease Market Size by Region (2021-2026)
- 1.5.3 Neurodegenerative Disease Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Neurodegenerative Disease Market Dynamics
- 2.1 Neurodegenerative Disease Industry Trends
- 2.2 Neurodegenerative Disease Industry Drivers
- 2.3 Neurodegenerative Disease Industry Opportunities and Challenges
- 2.4 Neurodegenerative Disease Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Neurodegenerative Disease Revenue by Company (2021-2026)
- 3.2 Global Neurodegenerative Disease Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Neurodegenerative Disease Key Company Head office and Area Served
- 3.4 Global Neurodegenerative Disease Company, Product Type & Application
- 3.5 Global Neurodegenerative Disease Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Neurodegenerative Disease Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Neurodegenerative Disease Players Market Share by Revenue in 2025
- 3.6.3 2025 Neurodegenerative Disease Tier 1, Tier 2, and Tier 3
4 Neurodegenerative Disease Market by Type
- 4.1 Global Neurodegenerative Disease Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Neurodegenerative Disease Market Size by Type (2021-2032)
- 4.3 Global Neurodegenerative Disease Market Size Share by Type (2021-2032)
5 Neurodegenerative Disease Market by Application
- 5.1 Global Neurodegenerative Disease Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Neurodegenerative Disease Market Size by Application (2021-2032)
- 5.3 Global Neurodegenerative Disease Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Biogen Idec
- 6.1.1 Biogen Idec Company Information
- 6.1.2 Biogen Idec Business Overview
- 6.1.3 Biogen Idec Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Biogen Idec Neurodegenerative Disease Product Portfolio
- 6.1.5 Biogen Idec Recent Developments
- 6.2 Boehringer Ingelheim
- 6.2.1 Boehringer Ingelheim Company Information
- 6.2.2 Boehringer Ingelheim Business Overview
- 6.2.3 Boehringer Ingelheim Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Boehringer Ingelheim Neurodegenerative Disease Product Portfolio
- 6.2.5 Boehringer Ingelheim Recent Developments
- 6.3 Merck Serono
- 6.3.1 Merck Serono Company Information
- 6.3.2 Merck Serono Business Overview
- 6.3.3 Merck Serono Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Merck Serono Neurodegenerative Disease Product Portfolio
- 6.3.5 Merck Serono Recent Developments
- 6.4 UCB
- 6.4.1 UCB Company Information
- 6.4.2 UCB Business Overview
- 6.4.3 UCB Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 UCB Neurodegenerative Disease Product Portfolio
- 6.4.5 UCB Recent Developments
- 6.5 BORA PHARMACEUTICALS
- 6.5.1 BORA PHARMACEUTICALS Company Information
- 6.5.2 BORA PHARMACEUTICALS Business Overview
- 6.5.3 BORA PHARMACEUTICALS Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 BORA PHARMACEUTICALS Neurodegenerative Disease Product Portfolio
- 6.5.5 BORA PHARMACEUTICALS Recent Developments
- 6.6 Dongcheng Biochemicals
- 6.6.1 Dongcheng Biochemicals Company Information
- 6.6.2 Dongcheng Biochemicals Business Overview
- 6.6.3 Dongcheng Biochemicals Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Dongcheng Biochemicals Neurodegenerative Disease Product Portfolio
- 6.6.5 Dongcheng Biochemicals Recent Developments
- 6.7 Ark Pharmaceutical
- 6.7.1 Ark Pharmaceutical Company Information
- 6.7.2 Ark Pharmaceutical Business Overview
- 6.7.3 Ark Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Ark Pharmaceutical Neurodegenerative Disease Product Portfolio
- 6.7.5 Ark Pharmaceutical Recent Developments
- 6.8 GlaxoSmithKline
- 6.8.1 GlaxoSmithKline Company Information
- 6.8.2 GlaxoSmithKline Business Overview
- 6.8.3 GlaxoSmithKline Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 GlaxoSmithKline Neurodegenerative Disease Product Portfolio
- 6.8.5 GlaxoSmithKline Recent Developments
- 6.9 Haisco Pharmaceutical
- 6.9.1 Haisco Pharmaceutical Company Information
- 6.9.2 Haisco Pharmaceutical Business Overview
- 6.9.3 Haisco Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Haisco Pharmaceutical Neurodegenerative Disease Product Portfolio
- 6.9.5 Haisco Pharmaceutical Recent Developments
- 6.10 Hisun Pharmaceutical
- 6.10.1 Hisun Pharmaceutical Company Information
- 6.10.2 Hisun Pharmaceutical Business Overview
- 6.10.3 Hisun Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Hisun Pharmaceutical Neurodegenerative Disease Product Portfolio
- 6.10.5 Hisun Pharmaceutical Recent Developments
- 6.11 Huahai Pharmaceutical
- 6.11.1 Huahai Pharmaceutical Company Information
- 6.11.2 Huahai Pharmaceutical Business Overview
- 6.11.3 Huahai Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Huahai Pharmaceutical Neurodegenerative Disease Product Portfolio
- 6.11.5 Huahai Pharmaceutical Recent Developments
- 6.12 Pfizer
- 6.12.1 Pfizer Company Information
- 6.12.2 Pfizer Business Overview
- 6.12.3 Pfizer Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Pfizer Neurodegenerative Disease Product Portfolio
- 6.12.5 Pfizer Recent Developments
- 6.13 Jingxin Pharmaceutical
- 6.13.1 Jingxin Pharmaceutical Company Information
- 6.13.2 Jingxin Pharmaceutical Business Overview
- 6.13.3 Jingxin Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Jingxin Pharmaceutical Neurodegenerative Disease Product Portfolio
- 6.13.5 Jingxin Pharmaceutical Recent Developments
- 6.14 Kanghong Pharmaceutical
- 6.14.1 Kanghong Pharmaceutical Company Information
- 6.14.2 Kanghong Pharmaceutical Business Overview
- 6.14.3 Kanghong Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Kanghong Pharmaceutical Neurodegenerative Disease Product Portfolio
- 6.14.5 Kanghong Pharmaceutical Recent Developments
- 6.15 Livzon Pharmaceutical
- 6.15.1 Livzon Pharmaceutical Company Information
- 6.15.2 Livzon Pharmaceutical Business Overview
- 6.15.3 Livzon Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Livzon Pharmaceutical Neurodegenerative Disease Product Portfolio
- 6.15.5 Livzon Pharmaceutical Recent Developments
- 6.16 Luye Pharma
- 6.16.1 Luye Pharma Company Information
- 6.16.2 Luye Pharma Business Overview
- 6.16.3 Luye Pharma Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Luye Pharma Neurodegenerative Disease Product Portfolio
- 6.16.5 Luye Pharma Recent Developments
- 6.17 Novartis
- 6.17.1 Novartis Company Information
- 6.17.2 Novartis Business Overview
- 6.17.3 Novartis Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 Novartis Neurodegenerative Disease Product Portfolio
- 6.17.5 Novartis Recent Developments
- 6.18 Sanofi
- 6.18.1 Sanofi Company Information
- 6.18.2 Sanofi Business Overview
- 6.18.3 Sanofi Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 Sanofi Neurodegenerative Disease Product Portfolio
- 6.18.5 Sanofi Recent Developments
- 6.19 TEVA
- 6.19.1 TEVA Company Information
- 6.19.2 TEVA Business Overview
- 6.19.3 TEVA Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.19.4 TEVA Neurodegenerative Disease Product Portfolio
- 6.19.5 TEVA Recent Developments
7 North America
- 7.1 North America Neurodegenerative Disease Market Size (2021-2032)
- 7.2 North America Neurodegenerative Disease Market Size by Type
- 7.2.1 North America Neurodegenerative Disease Market Size by Type (2021-2026)
- 7.2.2 North America Neurodegenerative Disease Market Size by Type (2027-2032)
- 7.2.3 North America Neurodegenerative Disease Market Share by Type (2021-2032)
- 7.3 North America Neurodegenerative Disease Market Size by Application
- 7.3.1 North America Neurodegenerative Disease Market Size by Application (2021-2026)
- 7.3.2 North America Neurodegenerative Disease Market Size by Application (2027-2032)
- 7.3.3 North America Neurodegenerative Disease Market Share by Application (2021-2032)
- 7.4 North America Neurodegenerative Disease Market Size by Country
- 7.4.1 North America Neurodegenerative Disease Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Neurodegenerative Disease Market Size by Country (2021-2026)
- 7.4.3 North America Neurodegenerative Disease Market Size by Country (2027-2032)
- 7.4.4 North America Neurodegenerative Disease Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Neurodegenerative Disease Market Size (2021-2032)
- 8.2 Europe Neurodegenerative Disease Market Size by Type
- 8.2.1 Europe Neurodegenerative Disease Market Size by Type (2021-2026)
- 8.2.2 Europe Neurodegenerative Disease Market Size by Type (2027-2032)
- 8.2.3 Europe Neurodegenerative Disease Market Share by Type (2021-2032)
- 8.3 Europe Neurodegenerative Disease Market Size by Application
- 8.3.1 Europe Neurodegenerative Disease Market Size by Application (2021-2026)
- 8.3.2 Europe Neurodegenerative Disease Market Size by Application (2027-2032)
- 8.3.3 Europe Neurodegenerative Disease Market Share by Application (2021-2032)
- 8.4 Europe Neurodegenerative Disease Market Size by Country
- 8.4.1 Europe Neurodegenerative Disease Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Neurodegenerative Disease Market Size by Country (2021-2026)
- 8.4.3 Europe Neurodegenerative Disease Market Size by Country (2027-2032)
- 8.4.4 Europe Neurodegenerative Disease Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Neurodegenerative Disease Market Size (2021-2032)
- 9.2 China Neurodegenerative Disease Market Size by Type
- 9.2.1 China Neurodegenerative Disease Market Size by Type (2021-2026)
- 9.2.2 China Neurodegenerative Disease Market Size by Type (2027-2032)
- 9.2.3 China Neurodegenerative Disease Market Share by Type (2021-2032)
- 9.3 China Neurodegenerative Disease Market Size by Application
- 9.3.1 China Neurodegenerative Disease Market Size by Application (2021-2026)
- 9.3.2 China Neurodegenerative Disease Market Size by Application (2027-2032)
- 9.3.3 China Neurodegenerative Disease Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Neurodegenerative Disease Market Size (2021-2032)
- 10.2 Asia Neurodegenerative Disease Market Size by Type
- 10.2.1 Asia Neurodegenerative Disease Market Size by Type (2021-2026)
- 10.2.2 Asia Neurodegenerative Disease Market Size by Type (2027-2032)
- 10.2.3 Asia Neurodegenerative Disease Market Share by Type (2021-2032)
- 10.3 Asia Neurodegenerative Disease Market Size by Application
- 10.3.1 Asia Neurodegenerative Disease Market Size by Application (2021-2026)
- 10.3.2 Asia Neurodegenerative Disease Market Size by Application (2027-2032)
- 10.3.3 Asia Neurodegenerative Disease Market Share by Application (2021-2032)
- 10.4 Asia Neurodegenerative Disease Market Size by Country
- 10.4.1 Asia Neurodegenerative Disease Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Neurodegenerative Disease Market Size by Country (2021-2026)
- 10.4.3 Asia Neurodegenerative Disease Market Size by Country (2027-2032)
- 10.4.4 Asia Neurodegenerative Disease Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Neurodegenerative Disease Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Neurodegenerative Disease Market Size by Type
- 11.2.1 South America, Middle East & Africa Neurodegenerative Disease Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Neurodegenerative Disease Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Neurodegenerative Disease Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Neurodegenerative Disease Market Size by Application
- 11.3.1 South America, Middle East & Africa Neurodegenerative Disease Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Neurodegenerative Disease Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Neurodegenerative Disease Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Neurodegenerative Disease Market Size by Country
- 11.4.1 South America, Middle East & Africa Neurodegenerative Disease Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Neurodegenerative Disease Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Neurodegenerative Disease Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Neurodegenerative Disease Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst